Drug Profile
Research programme: oral anthrax vaccine - Emisphere Technologies/USAMRIID
Latest Information Update: 14 Dec 2020
Price :
$50
*
At a glance
- Originator Emisphere Technologies; United States Army Medical Research Institute of Infectious Diseases
- Class Anthrax vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Anthrax
Most Recent Events
- 08 Dec 2020 Emisphere Technologies has been acquired by Novo Nordisk
- 08 Aug 2005 This programme is still in active development - BIO 2005: Annual International Convention (BIO 2005)
- 04 Jul 2003 Preclinical trials in Anthrax in USA (PO)